Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

EHA 2023 | Menin inhibitors in AML: providing options for patients with NPM1 mutation and KMT2A rearrangement

Eunice Wang • 9 Jun 2023
EHA 2023
Acute Myeloid Leukemia Leukemia

Eunice Wang, MD, Roswell Park Comprehensive Cancer Center, Buffalo, NY, briefly discusses the rationale behind using menin inhibitors to treat patients with acute myeloid leukemia (AML), highlighting the important role of these agents in patients with NPM1 mutation and KMT2A rearrangement. This interview took place at the 28th Congress of the European Hematology Association (EHA) 2023 in Frankfurt, Germany.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.

More from Eunice Wang

2:49
Results of a Phase I trial investigating CYNK-001, a placental NK-cell product, in patients with AML
Eunice Wang • 10 Dec 2023
1:30
A Phase I trial investigating a novel oral FLT3 inhibitor, BMF-500, in FLT3-mutant AML
Eunice Wang • 10 Dec 2023
3:03
The effect of BMI on survival outcomes in adolescents and young adults with AML
Eunice Wang • 10 Dec 2023
Novel targets, combinations & treatments
Eunice Wang et al. • 4 Sep 2023

Related Videos

1:40
The role of CPX-351 in the AML treatment landscape & insights into the AMLSG 30-18 trial
Felicitas Thol • 19 Apr 2024
3:21
Integrating genomics and MRD in transplant decision-making for patients with AML
Jurjen Versluis • 22 Apr 2024
4:19
Blinatumomab to achieve remission and consolidation with haploSCT for pediatric ALL
Alberto Olaya-Vargas • 15 Apr 2024
3:32
Improving CAR-T therapy for ALL & lymphoma: allogeneic products & reducing CRS/ICANS
Sridhar Chaganti • 16 Apr 2024
The content of VJHemOnc is intended for healthcare professionals